Double-Cycle, High-Dose Ifosfamide, Carboplatin, and Etoposide Followed by Peripheral Blood Stem-Cell Transplantation for Small Cell Lung Cancer*
|
|
- Horace McCarthy
- 6 years ago
- Views:
Transcription
1 Double-Cycle, High-Dose Ifosfamide, Carboplatin, and Etoposide Followed by Peripheral Blood Stem-Cell Transplantation for Small Cell Lung Cancer* Yoshinobu Iwasaki, MD, PhD; Kazuhiro Nagata, MD; Masaki Nakanishi, MD; Atsushi Natuhara, MD; Yutaka Kubota, MD; Mikio Ueda, MD; Taichiro Arimoto, MD, PhD; and Hiroshi Hara, MD, PhD Purpose: To determine the tolerability and feasibility of double-cycle, high-dose chemotherapy followed by peripheral blood stem-cell transplantation (PBSCT) after conventional chemotherapy or chemoradiotherapy for small cell lung cancer (SCLC). Patients and methods: Patients with previously untreated SCLC received two cycles of cisplatin, 80 mg/m 2, and etoposide, 300 mg/m 2 (cisplatin-etoposide [PE]). Later, they were administered high-dose etoposide, 1,500 mg/m 2, followed by granulocyte colony-stimulating factor for collection of peripheral blood stem cells. After two additional cycles of PE, the patients received high-dose ifosfamide, 10 g/m 2, carboplatin, 1,200 mg/m 2, and etoposide, 1,000 mg/m 2 (ifosfamidecarboplatin-etoposide [ICE]) followed by PBSCT twice at 3-month to 4-month intervals. Patients with limited disease (LD) concurrently received 50 Gy of irradiation with the last two cycles of PE. Results: Eighteen patients, including 11 patients with LD, were enrolled. Fifteen patients could receive high-dose ICE followed by PBSCT twice, and 3 patients could receive it once. The median number of CD34 cells collected was /kg. The median numbers of days to neutrophil counts > 500/ L and platelet counts > 50,000/ L were 10 days and 14.5 days after the first PBSCT, and 10 days and 15 days after the second PBSCT, respectively. Grade 3 diarrhea occurred in one cycle, and grade 3 renal toxicity occurred in two cycles. The overall response rate was 100%, with an 83.3% rate of complete or near-complete response. The 2-year and 5-year survival rates were 72% and 55% in patients with LD and 43% and 0% in patients with extensive disease, respectively. Conclusion: Double-cycle, high-dose ICE therapy followed by PBSCT is tolerable and feasible even after conventional chemotherapy or chemoradiotherapy in patients with SCLC. (CHEST 2005; 128: ) Key words: high-dose chemotherapy; peripheral blood stem-cell transplantation; small cell lung cancer Abbreviations: ABMT autologous bone marrow transplantation; CR complete response; ED extensive disease; G-CSF granulocyte colony-stimulating factor; ICE ifosfamide-carboplatin-etoposide; LD limited disease; ncr near complete response; PBSC peripheral blood stem cell; PBSCT peripheral blood stem-cell transplantation; PE cisplatin-etoposide; PR partial response; SCLC small cell lung cancer Combination chemotherapy with cisplatin and etoposide (cisplatin-etoposide [PE]) has long been the mainstay of treatment for small cell lung cancer (SCLC). Response rates in extensive disease (ED) range from 51 to 78%, including a7to13% rate of complete response (CR) and a median survival of 8 to 9 months. In patients with limited *From the Division of Pulmonary Medicine, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. Manuscript received January 30, 2005; revision accepted April 26, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( org/misc/reprints.shtml). disease (LD), the CR rate is 16 to 18%, with a median survival of 11.7 to 12.4 months. 1 3 Given the exquisite initial sensitivity of SCLC to chemotherapy and the high rate of relapse, some studies have attempted to improve survival by increasing dose intensity. Within conventional ranges, dose intensity can be increased with the support of hematopoietic growth factors. One approach to treatment is the rapid sequencing of several active agents over a short period. 4 6 Another approach is Correspondence to: Yoshinobu Iwasaki, MD, PhD, Division of Pulmonary Medicine, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602, Japan; yiwasaki@koto.kpu-m.ac.jp 2268 Clinical Investigations
2 the use of higher doses of chemotherapy, particularly during the first four cycles of treatment. 7,8 The dose intensity of chemotherapy has also been increased by reducing the interval between chemotherapy cycles with the use of hematopoietic growth factors However, whether such approaches improve survival as compared with standard therapy remains controversial. Autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (PBSCT) have been used in many studies to control the hematologic toxicity of high-dose chemotherapy, thereby permitting a further increase in dose intensity. Most studies have evaluated late intensification strategies, in which a single course of intensive chemotherapy is administered to consolidate the response to standard treatment. A combined analysis 13 revealed no apparent improvement in survival, even though the percentage of complete responders almost doubled. Another study 14 proposed that lateintensification chemotherapy might improve longterm survival in a significant proportion of complete responders with LD. To date, only one randomized, phase III trial 15 of high-dose chemotherapy followed by ABMT or PBSCT has been completed in patients with SCLC. Significant differences favoring highdose chemotherapy were seen with respect to relapse-free survival, 15 suggesting that double-cycle, high-dose chemotherapy with ABMT or PBSCT might prolong survival by reducing the relapse rate. Multiple cycles of high-dose chemotherapy have been used as first-line therapy, 16 not for late intensification. Recently, the safety of high-dose chemotherapy has been enhanced by improvements in supportive care, including the use of hematopoietic growth factors and peripheral blood stem cells (PBSCs). The most recent studies have evaluated ifosfamide, carboplatin, and etoposide (ifosfamide-carboplatin-etoposide [ICE]) therapy, considered to have a favorable therapeutic index A steep dose response coupled with synergistic antitumor activity and a favorable spectrum of nonhematopoietic toxicity makes this combination a natural candidate for high-dose therapy. 20 A phase I dose-escalation study of high-dose ICE therapy followed by ABMT or PBSCT was conducted by Fields et al 21 to determine the maximum tolerated dose. They reported that the maximum tolerated dose of ICE was 20,100 mg/m 2 of ifosfamide, 1,800 mg/m 2 of carboplatin, and 3,000 mg/m 2 of etoposide. The dose-limiting toxicities of ICE were CNS toxicity and acute renal failure. Leyvraz et al 16 showed that three cycles of high-dose ICE therapy could be safely administered as firstline therapy. In their study, three cycles of high-dose ICE therapy with 10 g/m 2 of ifosfamide, 1,200 mg/m 2 of carboplatin, and 1,200 mg/m 2 of etoposide were administered over the course of 4 days at 4-week intervals. We treated patients with double-cycle, high-dose chemotherapy followed by PBSCT after conventional chemotherapy or chemoradiotherapy. Our main objective was to examine whether doublecycle, high-dose chemotherapy with ICE can be delivered with acceptable toxicity after conventional chemotherapy or chemoradiotherapy. Patients Materials and Methods Patients with histologically confirmed SCLC of any stage were eligible for the study. Eligibility criteria included the following: (1) no previous treatment, including radiotherapy, chemotherapy, and surgery; (2) lesions that could be measured or assessed; (3) age 18 to 65 years; (4) an Eastern Cooperative Oncology Group performance status of 0 or 1; (5) a life expectancy of 12 weeks; (6) a blood count within the normal range, and normal cardiac, hepatic, and renal functions; and (7) Pao 2 70 mm Hg in a sample of arterial blood in patients with LD. As for renal function, a serum creatinine level 1.5 mg/dl and a creatinine clearance 60 ml/min were required at entry, immediately before the first high-dose chemotherapy, and immediately before the second high-dose chemotherapy. This study was approved by our institutional review board, and all patients provided their informed consent before enrollment. Before study entry, all patients underwent staging investigations, including physical examination, chest radiography, CT of the chest and abdomen, brain MRI, bone scintigraphy, full blood count, electrolyte measurements, liver and renal function tests, and fiberoptic bronchoscopy with biopsy. LD was defined as tumor confined to one hemithorax with or without ipsilateral supraclavicular lymphadenopathy. All other patients were defined as having ED. Treatment Induction Therapy and PBSC Collection: The treatment scheme is outlined in Figure 1. Patients initially received two cycles of chemotherapy with PE at 3-week intervals. Cisplatin was administered at a dose of 80 mg/m 2 on day 1. Etoposide was administered at a dose of 100 mg/m 2 on days 1, 2, and 3. Four weeks after the first two cycles of PE, patients were administered 300 mg/m 2 of etoposide IV on days 1 to 5, followed by granulocyte colony-stimulating factor (G-CSF), 50 g/m 2 /d subcutaneously, to mobilize stem cells into the blood. PBSCs were collected by leukapheresis and cryopreserved. Collection was performed up to three times, until sufficient PBSCs were obtained to support two cycles of high-dose chemotherapy. Consecutively, two additional cycles of PE were administered at 3-week intervals. High-Dose Therapy Followed by PBSCT: Three weeks after the last two cycles of PE, patients received high-dose ICE therapy. Ifosfamide was administered at 2.5 g/m 2 /d as a 3-h IV infusion for 4 days. Carboplatin was administered at 300 mg/m 2 /d as a 6-h IV infusion for 4 days. Etoposide was administered at 200 mg/m 2 /d as a continuous infusion for 5 days. Mesna, 1,000 mg/m 2, was administered as a 1-h IV infusion 1 h before ifosfamide administration. Subsequently, mesna was adminiswww.chestjournal.org CHEST / 128 / 4/ OCTOBER,
3 Results Patients Characteristics Twenty patients were enrolled at our hospital between 1995 and Two patients were excluded: one patient declined to receive high-dose chemotherapy, and the other patient had a cerebral infarction during the second cycle of PE. The clinical characteristics of the patients data are shown in Table 1. The median age was 58 years (range, 46 to 65 years). Fourteen patients were men. Eleven patients had LD, and 7 patients had ED. Figure 1. Treatment schedule. VP-16 etoposide; PBSCC PBCS collection; TRT thoracic radiotherapy; IFO ifosfamide; CBDCA carboplatin; d1 5 days1to5;d7 day 7. tered at 4,000 mg/m 2 /d as a continuous infusion for 4 days. Forty-eight hours after the end of chemotherapy, PBSCs were reinfused and G-CSF was introduced at 50 g/kg/d, administered subcutaneously until hematopoietic recovery. If sufficient PBSCs were obtained to allow transplantation twice, a second course of high-dose ICE therapy was administered 3 to 4 months after the first course. Radiotherapy: Patients with LD received a total dose of 50 Gy of thoracic radiotherapy concurrently with the last two cycles of PE (2.0 Gy/d in 25 fractions over a period of 5 weeks). The target volume for thoracic radiotherapy included the gross tumor, as defined by the chest CT scan, and the bilateral mediastinal and ipsilateral hilar lymph nodes. If involved by tumor, the supraclavicular lymph nodes were also irradiated. The clinically determined volume was expanded by a 1.5-cm margin. After the first course of high-dose ICE therapy, prophylactic whole-brain irradiation was administered to patients with a CR or near-cr (ncr) from the year The brain irradiation consisted of 15 doses of 2.0 Gy over the course of 3 weeks, for a total dose of 30 Gy. Assessment of Toxicity, Response, and Survival General toxicity was classified according to the National Cancer Institute common toxicity criteria. Response was determined by clinical examination and chest CT. Bronchoscopy with biopsy was performed. Response was defined as follows: (1) CR, if all target lesions disappeared; (2) ncr, if there was a 90% reduction in the sum of the longest diameters of target lesions with persistent radiographic abnormalities; and (3) partial response (PR), if the reduction was at least a 30% reduction in the sum of the longest diameters of target lesions. Response had to be present for 4 weeks with no lesion recurrence. Stable disease was defined as a 30% reduction or 20% increase in the sum of the longest diameters of target lesions for 8 weeks. Restaging was done by chest CT, brain MRI, and bronchoscopy with biopsy in all patients three times: just before the first high-dose ICE therapy, 4 weeks after the first high-dose ICE therapy, and 4 weeks after the second high-dose ICE therapy. In addition, abdomen CT, bone scintigraphy, or both were performed in patients with distant metastasis to evaluate metastatic lesions. Overall survival was calculated from the first day of chemotherapy to the day of death using the Kaplan-Meier method. The patients were followed up for at least 5 years from the start of treatment. Leukaphereses and PBSC Collection After administration of etoposide, 1,500 mg/m 2 IV, over the course of 5 days, G-CSF was administered at 50 g/kg/d for a median of 12 days (range, 10 to 14 days). The interval from day 1 of mobilization to the start of leukapheresis was 17 days (range, 15 to 19 days). The median number of leukaphereses performed per patient was two (range, one to three procedures). The median number of CD34 cells collected was /kg (range, 3.55 to /kg). Grade 4 neutropenia occurred in all patients for a median of 5 days (range, 4 to 6 days), and five patients had febrile neutropenia. Hematopoietic Recovery Among the 18 patients, 15 patients received highdose ICE therapy followed by PBSCT twice. The other three patients did not receive the second course of high-dose ICE: two patients had grade 3 renal toxicity during the first course of high-dose ICE, and the other patient lacked sufficient cells for the second PBSCT. The median number of CD34 cells reinfused was /kg (range, 1.4 to /kg) in the first PBSCT and /kg (range, 1.50 to /kg) in the second PBSCT. The median time from PBSCT to a neutrophil count Table 1 Patient Characteristics (n 18) Characteristics No. Age, yr Median 58 Range Sex Male 14 Female 4 Performance status Disease status LD 11 ED Clinical Investigations
4 500/ L was 10 days (range, 8 to 14 days) in the first PBSCT and 10 days (range, 8 to 13 days) in the second PBSCT. The median time from PBSCT to a platelet count 50,000/ L was 14.5 days (range, 11 to 28 days) in the first PBSCT and 15 days (range, 12 to 24 days) in the second PBSCT. There were no differences in hematopoietic recovery between the first and second PBSCT. Nonhematologic Toxicity A total of 33 cycles of high-dose ICE therapy were analyzed for nonhematologic toxicity (Table 2). Grade 3 diarrhea occurred in one cycle, and grade 3 renal toxicity in two cycles. Infectious complications occurred in 16 cycles. Response and Survival Among the 18 patients evaluated, the response to treatment at study end point was CR in 13 patients, ncr in 2 patients, and PR in 2 patients. PE or PE with concurrent radiotherapy led to a CR or ncr in 10 patients and a PR in 5 patients. Two of the patients with PR had a CR after high-dose ICE therapy. The 2-year and 5-year survival rates were 72% and 55% in patients with LD, and 43% and 0% in those with ED, respectively (Fig 2). Discussion Table 2 Nonhematologic Toxicity in High-Dose ICE (n 33) Variables No. of Cycles Nausea Grade 11/10 Grade 3 10 Vomiting Grade 1/grade 2 2/5 Grade 3/grade 4 3/0 Diarrhea Grade 1/grade 2 6/5 Grade 3/grade 4 1/0 Renal Grade 1/grade 2 4/3 Grade 3/grade 4 2/0 Liver dysfunction Grade 1/grade 2 11/15 Grade 3/grade 4 0/0 Figure 2. Kaplan-Meier survival curves of patients with LD (continuous line) and those with ED (dotted line). 2YS 2-year survival rate; 5YS 5-year survival rate. In the 1980s, high-dose chemotherapy with ABMT was administered as first-line treatment. The rationale of early intensification schedules was to intensify therapy for all patients, while avoiding drug resistance induced by previous chemotherapy In the late 1990s, multicyclic high-dose chemotherapy supported by PBSCT or whole blood transfusions was used as an early intensification strategy. 16,24 This approach resulted in high rates of complete remission (56% to 67%) among patients with LD. Late-intensification schedules, in which conventional chemotherapy is initially administered to debulk the tumor, followed by high-dose chemotherapy to promote consolidation, were also tried. In the 1980s, ABMT was used as hematopoietic support ; PB- SCT has been used more recently. 17,18 High-dose chemotherapy appears to be more toxic when used for late intensification than for early intensification, with much higher treatment-related mortality associated with the former than the latter. However, high-dose chemotherapy can be administered more safely and effectively owing to improvements in supportive care, including the availability of hematopoietic growth factors and improved techniques for PBSCT. We initially administered four cycles of PE with concurrent radiotherapy to patients with LD and four cycles of PE alone to those with ED to derive the full effect of conventional chemotherapy or chemoradiotherapy and decrease tumor volume. The patients then received double-cycle, high-dose ICE therapy. There was no mortality related to high-dose ICE therapy followed by PBSCT. Among the 18 patients evaluated, 10 patients had a CR or ncr after PE or PE with concurrent radiotherapy. Among the five patients with a PR, two had a CR after high-dose ICE therapy. The 2-year and 5-year survival rates were 72% and 55% in patients with LD and 43% and 0% in patients with ED, respectively. In our study, double-cycle, high-dose ICE therapy was administered according to a late-intensification protocol. Our initial concern was that toxicity might cumulatively increase during the second course of high-dose ICE therapy, but this concern proved to CHEST / 128 / 4/ OCTOBER,
5 be unfounded. The doses of ICE were similar to those used in previous studies. 16,18 Among 33 administered cycles of high-dose ICE therapy, reversible severe diarrhea occurred in one cycle and reversible severe renal toxicity occurred in two cycles. The median number of days from PBSCT to a neutrophil count 500/ L was 10 days in both the first and second PBSCTs, and the median number of days from PBSCT to a platelet count 50,000/ L was 14.5 days in the first PBSCT and 15 days in the second PBSCT. The first PBSCT and second PBSCT thus had similar times to hematopoietic recovery. The schedules and dosages of ICE regimens have differed considerably among clinical trials. Although unequivocal conclusions cannot be made, several trends have emerged. First, ICE 16,17 regimens are apparently associated with better results of survival. Our results support a good outcome in terms of survival as well as response. Second, ICE regimens permit double cycles of intensification, without a cumulative increase in toxicity, even after conventional chemotherapy or chemoradiotherapy. We conclude that sequential, double-cycle, high-dose ICE therapy is tolerable and feasible in patients with SCLC, including those who have already received full courses of conventional chemotherapy or chemoradiotherapy. References 1 Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: a multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987; 107: Murray N, Shah A, Osoba D, et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 1991; 83: Furuse K, Fukuoka M, Nishiwaki Y, et al. Phase III study of granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. J Clin Oncol 1998; 16: Murray N, Livingston RB, Shephers FA, et al. Randomized study of CODE versus alternating CAV/EP for extensivestage small-cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999; 17: Arriagada R, Le Chevalier T, Pierre Pignon J, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 25: Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensivestage small-cell lung cancer. J Clin Oncol 1994; 12: Steward WP, von Pawel J, Gatzemeier U, et al. Effect of granulocyte colony-stimulating factor and dose-intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study 300 patients. J Clin Oncol 1998; 16: Thatcher N, Girling DJ, Hopwood P, et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a BMJ Research Council multicenter randomized trial. J Clin Oncol 2000; 18: Bunn PA Jr., Crowley K, Kelly K, et al. Chemoradiotherapy with/ without granulocyte-macrophage colony-stimulating factor in the treatment of limited stage small cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13: Sculier JP, Paesmans M, Lecomte J, et al. A three-arm phase III randomized trial assessing, in patients with extensivedisease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer 2001; 85: Pasini F, Pelosi G, Manzoni G, et al. High-dose chemotherapy in small cell lung cancer. Tumori 2002; 88: Elias AD, Ibrahim J, Skavin AT, et al. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 1999; 17: Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5: Leyvraz S, Perey L, Rosti A, et al. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for blood and marrow transplantation. J Clin Oncol 1999; 17: Fetscher S, Brugger W, Engelhardt R, et al. Dose intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. Ann Oncol 1997; 8: Bessho A, Ueoka H, Kiura K, et al. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer. Anticancer Res 1999; 19: Van de Velde H, Bosquee L, Weynants P, et al. Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited disease small cell lung cancer: prolonged intrathoracic tumour control and high central nervous system relapse rate. Ann Oncol 1999; 10: Elias AD, Ayash LJ, Wheeler C, et al. Phase I study of high-dose ifosfamide, carboplatin, and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995; 15: Fields KK, Elfenbein GJ, Lazarus HM, et al. Maximumtolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol 1995; 13: Souhami RI, Finn G, Gregory WM, et al. High-dose cyclophosphamide in small-cell carcinoma of the lung. J Clin Oncol 1985; 3: Farha P, Spitzer G, Valdivieso M, et al. High-dose chemotherapy and autologous bone marrow transplantation for the 2272 Clinical Investigations
6 treatment of small cell lung carcinoma. Cancer 1983; 52: Pettengell R, Woll PJ, Thatcher N, et al. Multicyclic doseintensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995; 13: Klastersky J, Nicaise C, Longeval E, et al. Cisplatin, adriamycin, and etoposide (CAV) for remission induction of small cell bronchogenic carcinoma. Cancer 1982; 50: Stewart P, Buckner CD, Thomas ED, et al. Intensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung. Cancer Treat Rep 1983; 67: Stahel RA, Takvorian RW, Skarin AT, et al. Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. Eur J Cancer Clin Oncol 1984; 20: Ihde DC, Deisseroth AB, Lichter AS, et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol 1986; 4: CHEST / 128 / 4/ OCTOBER,
doi: /theoncologist
Increasing Chemotherapy in Small-Cell Lung Cancer: From Dose Intensity and Density to Megadoses Gino Crivellari, Silvio Monfardini, Silvia Stragliotto, Dario Marino and Savina Maria Luciana Aversa The
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM San Francisco, CA October 23, 2009 Speaker: Bruce E. Johnson, MD Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical
More informationCombination of three cytotoxic agents in small-cell lung cancer
Cancer Chemother Pharmacol (2013) 71:413 418 DOI 10.1007/s00280-012-2022-8 ORIGINAL ARTICLE Combination of three cytotoxic agents in small-cell lung cancer G. P. Stathopoulos D. Trafalis J. Dimitroulis
More informationThis document is the result of a comprehensive
Small Cell Lung Cancer* George R. Simon, MD, FCCP; and Henry Wagner, MD Among patients with lung cancers, the proportion of those with small cell lung cancer (SCLC) has decreased over the last decade.
More informationTHERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra,
THERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra, Slovakia Lancet. 1966;2(7471):979-86. First standard treatment:
More informationAn analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn
Review Annals of Oncology 13: 1519 1530, 2002 DOI: 10.1093/annonc/mdf249 An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn V. C. G. Tjan-Heijnen 1 *, D.
More informationSequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide
Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide Review Article [1] April 01, 1997 By Clifford A. Hudis, MD [2] The recognition of paclitaxel's (Taxol's) activity
More informationSmall cell lung cancer (SCLC) accounts for 13 to 15% of
ORIGINAL ARTICLE Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive Disease Small Cell Lung Cancer
More informationManagement of Small Cell Lung Cancer* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER: ACCP GUIDELINES Management of Small Cell Lung Cancer* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) George R. Simon, MD, FCCP; and Andrew
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationOriginal article. Introduction. survival times (MSTs) from 8 to 11 months in this patient population
Original article Annals of Oncology 14: 709 714, 2003 DOI: 10.1093/annonc/mdg213 Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive
More informationRadiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
More informationOriginal Study. 40 Clinical Lung Cancer January 2013
Original Study Prophylactic Cranial Irradiation for Patients With Limited-Stage Small-Cell Lung Cancer With Response to Chemoradiation Patricia Tai, 1 Avi Assouline, 2 Kurian Joseph, 3 Larry Stitt, 4 Edward
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationSMALL-CELL LUNG cancer (SCLC) represents 20% to
Cisplatin, Etoposide, and Paclitaxel in the Treatment of With Extensive Small-Cell Lung Carcinoma By Bonnie S. Glisson, Jonathan M. Kurie, Roman Perez-Soler, Nikolous J. Fox, William K. Murphy, Frank V.
More informationClinical Management Guideline for Small Cell Lung Cancer
Diagnosis and Staging: Key Points 1. Ensure a CT scan that is
More informationEffect of radiotherapy on the treatment of patients with extensive stage small cell lung cancer
Effect of radiotherapy on the treatment of patients with extensive stage small cell lung cancer C. Wu, T. Wang, J. Wang, B. Qu, H. Wang and Y. Hu Department of Oncology, The General Hospital of the People
More informationCarboplatin in the Treatment of Small Cell Lung Cancer
Carboplatin in the Treatment of Small Cell Lung Cancer JULIE R. BRAHMER, DAVID S. ETTINGER The Johns Hopkins Oncology Center Baltimore, Maryland, USA Key Words. Carboplatin Small cell lung cancer Extensive
More informationThe start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer
ORIGINAL ARTICLE Korean J Intern Med 2013;28:449-455 The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer Kyoung Ju Lee 1, Eun Joo Lee 2, Gyu Young
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationLung cancer is the most common cause of cancer-related
GUIDELINES Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline Susanna Cheng, MD,* William K. Evans, MD, Denise Stys-Norman, PgDip, Frances A. Shepherd, MD, and
More informationStandard care plan for Carboplatin and Etoposide Chemotherapy References
CHEMOTHERAPY CARE PLAN Document Title: Document Type: Subject: Approved by: Currency: Carboplatin/Etoposide Chemotherapy Clinical Guideline Standard Care Plan 2 Years Review date: Author(s): Standard care
More informationEffect of early chemoradiotherapy in patients with limited stage small cell lung cancer
Original Article Radiat Oncol J 2013;31(4):185-190 http://dx.doi.org/10.3857/roj.2013.31.4.185 pissn 2234-1900 eissn 2234-3156 Effect of early chemoradiotherapy in patients with limited stage small cell
More informationCombining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer
Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer Dr Martin Forster MD PhD Clinical Senior Lecturer in Experimental Cancer Medicine Consultant in Medical Oncology UCL
More informationBleomycin, Etoposide and CISplatin (BEP) Therapy
Bleomycin, Etoposide and CISplatin (BEP) Therapy INDICATIONS FOR USE: INDICATION ICD10 Regimen Code Adjuvant treatment of high risk (vascular invasion C62 00300a carcinoma) stage 1 nonseminoma germ cell
More informationSMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)
SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Desiree Hao (Staff Medical Oncologist, University of Calgary) and Dr.
More informationProtocol of Radiotherapy for Small Cell Lung Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Small Cell Lung Cancer Indication of radiotherapy Limited stage: AJCC (8th edition) stage I-III (T any, N any, M0) that can be safely treated with definitive RT
More informationEffective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationSmall-cell lung cancer (SCLC) is an aggressive neuroendocrine
ORIGINAL ARTICLE Tolerability of Accelerated Chest Irradiation and Impact on Survival of Prophylactic Cranial Irradiation in Patients with Limited-stage Small Cell Lung Cancer: Review of a Single Institution
More informationDA-EPOCH-R (Etoposide/Inpatient)
DA- (Etoposide/Inp) INDICATION High grade lymphoma. Omit rituximab if CD20 negative. PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy and document in notes. 2. Record
More informationBR for previously untreated or relapsed CLL
1 Protocol synopsis Title Rationale Study Objectives Multicentre phase II trial of bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia
More informationProphylactic cranial irradiation or no prophylactic cranial irradiation in metastatic small cell lung cancer: is it a relevant question once again?
Editorial Prophylactic cranial irradiation or no prophylactic cranial irradiation in metastatic small cell lung cancer: is it a relevant question once again? Cecile Le Pechoux 1, Angela Botticella 1, Antonin
More informationLung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000
More informationIs High-Dose Chemotherapy After Primary Chemotherapy a Therapeutic Option for Patients With Primary Mediastinal Nonseminomatous Germ Cell Tumor?
Biology of Blood and Marrow Transplantation 12:1085-1091 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1210-0001$32.00/0 doi:10.1016/j.bbmt.2006.06.008 Is High-Dose Chemotherapy
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationSetting The setting was secondary care. The economic study was carried out in the UK.
Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer Robinson P, von der Masse H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D
More informationNICaN Testicular Germ Cell Tumours SACT protocols
Reference No: Title: Author(s) Ownership: Approval by: Systemic Anti-Cancer Therapy (SACT) Guidelines for Germ Cell Tumours Dr Audrey Fenton Consultant Medical Oncologist, Dr Vicky Coyle Consultant Medical
More informationThe Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer
Evidence-based Series # 7-13-3 EDUCATION AND INFORMATION 2013 The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer Members of the Lung Cancer
More informationsymposium article introduction symposium article
Annals of Oncology 17 (Supplement 5): v118 v122, 2006 doi:10.1093/annonc/mdj965 Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/ vinblastine/doxorubicin/cisplatin
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME R-IVE.DOC CONTROLLED DOC NO: HCCPG B53 CSIS Regimen Name: R-IVE. R-IVE Regimen
R-IVE Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory
More informationCitation Cancer Management and Research, 2(1
NAOSITE: Nagasaki University's Ac Title Author(s) Efficacy and safety of amrubicin hy small cell lung cancer Ogawara, Daiki; Fukuda, Minoru; Nak Citation Cancer Management and Research, 2(1 Issue Date
More informationSmall Cell Lung Cancer What we have now?
Small Cell Lung Cancer What we have now? Chunxue Bai, M.D., Ph.D. Chair, Chinese Alliance against Lung Cancer Shanghai Respiratory Research Institute Department of Pulmonary Medicine Zhongshan Hospital,
More informationPoor-prognostic advanced Germ Cell Tumors
14-10-16 Poor-prognostic advanced Germ Cell Tumors Karim Fizazi, MD, PhD Institut Gustave Roussy, France Metastatic GCT: Prognosis (IGCCC) Good prognosis Intermediate prognosis Poor prognosis J Clin Oncol
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationSCLC: Developments in systemic treatment
SCLC: Developments in systemic treatment Egbert F. Smit, Dept. Pulmonary Diseases, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands Staging Outline First line treatment Second line treatment
More informationSAALT3W Sarcoma Dr. Meg Knowling. Protocol Code Tumour Group Contact Physician
BCCA Protocol Summary for Etoposide, Ifosfamide-Mesna (SAIME) Alternating with vincristine, DOXOrubicin and Cyclophosphamide (with or without Mesna)(SAVAC or SAVACM) with Filgrastim Support at a THREE
More information1 Oregon Health & Science University, Portland, OR 2 Stritch School of Medicine, Loyola University Chicago, Chicago, IL
Current treatment practices for limited-stage small cell lung cancer: A survey of US radiation oncologists on the timing of thoracic radiotherapy with chemotherapy Matthew J. Farrell 1, Jehan Yahya 1,
More informationBelotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer
J Lung Cancer 2010;9(1):15-19 Belotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer Purpose: Belotecan (Camtobell R ; Chong Keun Dang Co., Seoul,
More informationA Pilot Phase 2 Study of Surgical Treatment After Induction Chemotherapy for Resectable Stage I to lila Small Cell Lung Cancer*
preliminary report A Pilot Phase 2 Study of Surgical Treatment After Induction Chemotherapy for Resectable Stage I to lila Small Cell Lung Cancer* Katsuya Fujimori, MD/ Akira Yokoyama, MD; Yuzo Kurita,
More informationForm 2023 R2.0: Ovarian Cancer Pre-HSCT Data
Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More information2.07 Protocol Name: CHOP & Rituximab
2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing
More informationConcomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
More informationSmall cell lung cancer (SCLC) comprises approximately
Original Article Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients Gun Min Kim, MD,* Young Sam Kim, MD, PhD, Young Ae Kang, MD, PhD, Jae-Heon Jeong, MD, Sun
More informationAbstract and Schema. Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Abstract and Schema Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Description and Rationale: Low grade gliomas are among the most common primary CNS
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 December 2009 MOZOBIL 20 mg/ml, solution for injection Box containing 1 vial (CIP: 397 153-7) Applicant: GENZYME
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationClinical Guidelines for Managing Topotecan-Related Hematologic Toxicity
Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity DEBORAH ARMSTRONG, SEAMUS O REILLY Johns Hopkins Oncology Center, Baltimore, Maryland, USA Key Words. Topotecan Topoisomerase I inhibitor
More informationJ 13 (10) : , 1995 STUDY DESIGN AND CONDUCT
High-Dose Chemotherapy With Hematopoietic Rescue as Primary Treatment for Metastatic Breast Cancer: A Randomized Trial. Bezwoda WR, Seymour L and Dansey RD. J Clin Oncology, 13 (10) : 2483-2489, Oct 1995
More informationChapter 4: Small Cell Carcinoma of the Bladder: A Single Centre Study of 25 Cases Treated in Analogy to Small Cell Lung Cancer
Chapter 4: Small Cell Carcinoma of the Bladder: A Single Centre Study of 25 Cases Treated in Analogy to Small Cell Lung Cancer A. Bex J.A. Nieuwenhuijzen J.M. Kerst F. Pos H. van Boven W. Meinhardt S.
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma. TREATMENT INTENT Palliative or curative depending on context.
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, Gemcitabine, Dexamethasone &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma or high grade T cell non-hodgkin
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationCOX-2 inhibitor and irradiation. Saitama Cancer Center Kunihiko Kobayashi MD, PhD
COX-2 inhibitor and irradiation Saitama Cancer Center Kunihiko Kobayashi MD, PhD Synthesis of prostaglandins from arachidonic acid by cyclooxygenase (COX) enzymes JNCI 95:1440, 2003 Difference between
More informationPILOT STUDY OF CONCURRENT CHEMO-RADIOTHERAPY FOR ADVANCED NASOPHARYNGEAL CARCINOMA (Forum for Nuclear Cooperation in Asia)
PILOT STUDY OF CONCURRENT CHEMO-RADIOTHERAPY FOR ADVANCED NASOPHARYNGEAL CARCINOMA (Forum for Nuclear Cooperation in Asia) Dr. Miriam Joy C. Calaguas Dept. of Radiation Oncology St. Luke s Medical Center
More informationFREQUENCY OF THORACIC RADIOTHERAPY WITH CHEMOTHERAPY IN LIMITED SMALL-CELL LUNG CANCER
TWICE-DAILY COMPARED WITH ONCE-DAILY THORACIC RADIOTHERAPY IN LIMITED SMALL-CELL LUNG CANCER TREATED CONCURRENTLY WITH CISPLATIN AND ETOPOSIDE ANDREW T. TURRISI, III, M.D., KYUNGMANN KIM, PH.D., RONALD
More informationAll India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology
All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationChemotherapy in Lung Cancer
Special Issue Chemotherapy in Lung Cancer Keunchil Park, M.D. Division of Hematology / Oncology, Department of Medicine Sungkyunkwan University School of Medicine, Samsung Medical Center E-mail : kpark@smc.samsung.co.kr
More informationR-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement)
R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement) Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case
More informationFAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 5 COG-AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationNeuroblastoma. Elizabeth Roberts. Data Coordinator CIBMTR Data Managers Mentor. Tandem Meeting February 18
Neuroblastoma Elizabeth Roberts Data Coordinator CIBMTR Data Managers Mentor Tandem Meeting February 18 Objectives Know what neuroblastoma is, how it is diagnosed, and how it is treated Complete form 2026:
More informationNordic Protocol (MaxiCHOP/R-MaxiCHOP plus R-HDAraC)
Nordic Protocol (MaxiCHOP/R-MaxiCHOP plus R-HDAraC) Available for Routine Use in Burton in-patient Derby in-patient (First cycle if bulky disease & risk of tumour lysis syndrome) Burton day-case Derby
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationHematopoietic Growth Factors* Defining the Appropriate Clinical Role in Multimodality Cancer Therapy
Hematopoietic Growth Factors* Defining the Appropriate Clinical Role in Multimodality Cancer Therapy George D. Demetri, MD Laboratory investigations have begun to elucidate the regulatory molecules that
More informationSmall cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More informationThis is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21
R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationEfficacy of carbon-ion radiotherapy and high-dose chemotherapy for patients with unresectable Ewing s sarcoma family of tumors
DOI 10.1007/s10147-012-0480-y ORIGINAL ARTICLE Efficacy of carbon-ion radiotherapy and high-dose chemotherapy for patients with unresectable Ewing s sarcoma family of tumors Shintaro Iwata Tsukasa Yonemoto
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 21 JULY 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine,
More informationThe Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer
Curr. Treat. Options in Oncol. (2015) 16: 56 DOI 10.1007/s11864-015-0372-2 Lung Cancer (HA Wakelee, Section Editor) The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer Kaname Nosaki, M.D.
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationLung cancer remains the leading cause of cancer-related
ORIGINAL ARTICLE Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer Cancer and Leukemia Group B Study 39901 Stephen L. Graziano, MD,* James E. Herndon, II, PhD, Mark
More informationVincristine Ifosfamide Doxorubicin Etoposide (VIDE) Sarcoma
Systemic Anti Cancer Treatment Protocol Vincristine Ifosfamide Doxorubicin Etoposide (VIDE) Sarcoma PROTOCOL REF: MPHAVIDE (Version No: 1.0) Approved for use in: Ewings sarcoma Desmoplastic small round
More informationAdverse side effects associated to metronomic chemotherapy
Adverse side effects associated to metronomic chemotherapy Elisabetta Munzone, MD Division of Medical Senology Istituto Europeo di Oncologia Milano, Italy LDM: the optimal biological dose Although there
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationLocally advanced unresectable non small cell lung cancer
ORIGINAL ARTICLE Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small Cell Lung Cancer Ikuo Sekine,*
More information